Screener
Agios Pharmaceuticals AGIO Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's shares (diluted)?
- Agios Pharmaceuticals (AGIO) reported shares (diluted) of 59.5M in Q2 2026.
- How has Agios Pharmaceuticals's shares (diluted) changed year-over-year?
- Agios Pharmaceuticals's shares (diluted) increased by 2.7% year-over-year, from 57.9M to 59.5M.
- What is the long-term trend for Agios Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's shares (diluted) has grown at a -1.7% compound annual growth rate (CAGR), from 248.1M to 231.5M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Agios Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude